Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
New England Journal of Medicine·
- DOI
- 10.1056/nejmoa2516491
- PMID
- 42090792
- PMCID
- —
- OpenAlex
- W7160445170
- Study type
- Randomised controlled trial
- Publisher
- Massachusetts Medical Society
- Article type
- journal-article
- Integrity
- current
Why this research matters now
This work evaluates an alternative antigen presentation technology aimed at addressing ongoing respiratory disease burdens in aging populations. Successful validation of this platform could inform future immunization strategies targeting groups with historically reduced vaccine responsiveness.
Structured evidence summary
Research question
Does an investigational trivalent messenger RNA influenza immunization demonstrate comparable or improved protective effects and acceptable tolerability relative to a licensed standard-dose product in older adults?
Study design
Researchers conducted a phase 3, double-blind, randomized controlled trial comparing the experimental messenger RNA formulation against a commercially approved comparator. Participants were systematically allocated to one of the two intervention arms for evaluation throughout a single respiratory virus season.
Population and setting
The trial enrolled approximately forty thousand seven hundred community-dwelling individuals aged fifty years and older.
Main findings
The messenger RNA candidate achieved statistically significant superiority over the reference vaccine in preventing laboratory-confirmed influenza-like illness among the target demographic. Although predefined statistical thresholds for efficacy were successfully met, the investigational product generated substantially higher rates of transient injection-site and systemic symptoms compared to the standard comparator.
Public-health relevance
This work evaluates an alternative antigen presentation technology aimed at addressing ongoing respiratory disease burdens in aging populations. Successful validation of this platform could inform future immunization strategies targeting groups with historically reduced vaccine responsiveness.
Important limitations
The summary is constrained to the supplied single-article abstract and metadata, and requires the original paper for decision-grade interpretation.
GIDS interpretation
This article provides primary clinical trial data establishing the initial efficacy and safety profile of a novel messenger RNA influenza candidate for older adults. The findings serve as a reference point for tracking emerging immunization technologies and understanding platform-specific performance metrics in respiratory disease prevention.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.